AbbVie Inc. is a global biopharmaceutical company dedicated to developing advanced therapies that address some of the world's most complex health challenges. With a mission to improve patient outcomes through innovative treatments, AbbVie focuses on areas such as immunology, oncology, neuroscience, and virology. The company's strategy emphasizes research and development, leveraging cutting-edge science and technology to create breakthrough medications. AbbVie operates through a robust pipeline of products, including established therapies and new drug candidates, aiming to enhance the quality of life for patients worldwide while driving sustainable growth.

ABBVIE INC

AbbVie continues to demonstrate resilience in the face of significant challenges, particularly the loss of patent exclusivity for its flagship drug, Humira, and setbacks in clinical trials for a schizophrenia treatment. In 2024, the company reported a 9% decline in adjusted earnings per share, yet its revenue increased by 3.7%,...

AbbVie Demonstrates Resilience and Strong Growth Potential Amidst Challenges, Remains a Top Choice for Income Investors

AbbVie is navigating significant challenges, yet its resilience shines through with a revenue increase and a remarkable 52-year dividend growth streak. As the company adapts and invests in a promising pipeline, can it maintain its status as a top choice for income investors?